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1 |  INTRODUCTION
Mycobacterium tuberculosis(Mtb), the causative agent of tu-
berculosis (TB), is the world's most successful pathogen, with 
a higher mortality rate than HIV.1 In 2016, there were an esti-
mated 600 000 cases of both multi‐drug resistant TB (MDR‐
TB) and rifampicin‐resistant TB (RR‐TB), with 153 000 new 
cases detected in 2016.2 With only 54% of MDR‐TB and RR‐
TB successfully treated, there is a need to develop new drugs 
with unique modes of action.2
Amino acid biosynthesis is an attractive and validated tar-
get for anti‐mycobacterial drugs.3,4 Since the advent of whole 
genome sequencing (WGS), the genes involved in the synthe-
sis of all 20 amino acids in Mtb have been identified, enabling 
the deconvolution of their biosynthetic pathways.5 A number 
of studies have demonstrated that the enzymes involved in 
these pathways are essential for survival in nutrient‐limited 
environments, such as in the host.6,7 For example, auxotrophs 
for proline, tryptophan,8 lysine,9 arginine,10 methionine,11 
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Abstract
Anti‐tubercular drug discovery continues to be dominated by whole‐cell high‐
throughput screening campaigns, enabling the rapid discovery of new inhibitory 
chemical scaffolds. Target‐based screening is a popular approach to direct inhibitor 
discovery with a specified mode of action, eliminating the discovery of anti‐tubercu-
lar agents against unsuitable targets. Herein, a screening method has been developed 
using Mycobacterium bovis BCG to identify inhibitors of amino acid biosynthesis. 
The methodology was initially optimized using the known branched‐chain amino 
acid biosynthetic inhibitors metsulfuron‐methyl (MSM) and sulfometuron‐methyl 
(SMM), and subsequently, whole genome sequencing of resistant mutants and the 
use of over‐expressor strains confirming their mode of action. The GlaxoSmithKline 
compound library of small molecule inhibitors with known activity against 
Mycobacterium tuberculosis was then used to validate the screen. In this paper, we 
have shown that media supplementation with amino acids can rescue M bovis BCG 
from known amino acid synthesis inhibitors, MSM and SMM, in a pathway specific 
manner. The therapeutic potential of amino acid biosynthesis inhibitors emphasizes 
the importance of this innovative screen, enabling the discovery of compounds tar-
geting a multitude of related essential biochemical pathways, without limiting drug 
discovery toward a single target.
K E Y W O R D S
drug discovery, high‐throughput screening, tuberculosis
   | 247BURKE Et al.
cysteine,12 and branched‐chain amino acids,6,13,14 have 
demonstrated attenuation in murine infections. The essen-
tiality of other amino acid biosynthetic pathways including 
histidine and the aromatic amino acids phenylalanine, tyro-
sine and tryptophan has also been demonstrated.15-17 Many of 
these amino acid biosynthetic pathways have been suggested 
as attractive targets for drug development due to their im-
portance with bacterial growth, and the fact that many of the 
above amino acids are classified as essential in humans and 
lack human orthologs, thereby exhibiting selective toxicity.
Herein, we have developed a method to identify inhibitors 
of amino acid biosynthesis using a whole‐cell phenotypic 
screening approach. We have validated this method using 
two known inhibitors of branched‐chain amino acid synthe-
sis, metsulfuron‐methyl (MSM) and sulfometuron‐methyl 
(SMM), and screened an anti‐tubercular compound library 
from GSK which identified an inhibitor of tryptophan syn-
thesis. This targeted approach not only accelerates mode of 
action studies, but also focuses inhibitor discovery toward a 
suitable target.
2 |  METHODS
2.1 | Growth conditions for Mycobacterium 
bovis BCG and Mycobacterium smegmatis
Mycobacterium bovis BCG and M smegmatis cultures were 
grown in cell culture flasks in Middlebrook 7H9 media sup-
plemented with 10% v/v oleic acid, albumin, dextrose, and 
catalase (OADC), 0.2% v/v glycerol and 0.05% v/v Tween 
80. M bovis BCG culture strains were incubated at 37°C with 
5% CO2. M smegmatis culture strains were incubated at 37°C 
with shaking at 180 rpm. Cells containing plasmids pVV16k 
(Kanamycin resistance marker) and pMV261a (Apramycin 
resistance marker) were grown containing 25 μg/mL of the 
appropriate antibiotic in culture.
2.2 | MIC determination in liquid media
The liquid MIC of MSM and SMM for M bovis BCG and 
M smegmatis were conducted in Greiner black flat‐bottomed 
96‐well plates. Mid‐log (OD600nm 0.4‐0.8) cells were diluted 
to 1 × 106 cells/mL in Middlebrook 7H9 culture medium and 
were added to each well along with increasing concentrations 
of drug. MSM and SMM were made up in 100% dimethyl 
sulfoxide (DMSO) and added at a final concentration of 1% 
DMSO. A 1% DMSO only positive control and a 1 μmol/L 
rifampicin negative control were also used. A media only liq-
uid barrier was maintained around the entirety of the test 
wells to minimize evaporation. The 96‐well plates were incu-
bated 7 days for M bovis BCG and 24 hours for M smegmatis 
at 37°C with 5% CO2. After incubation, cell survival was 
monitored using resazurin.18 Briefly, 30 μL of 0.05% resa-
zurin and 12.25 μL of 20% tween 80 were added to every 
well and incubated for a further 24 hours for M bovis BCG 
and 2 hours for M smegmatis. Plates were then read using a 
BMG plater reader at excitation wavelength 544 nmol/L and 
detection wavelength 590 nmol/L. Percentage survival was 
calculated as per the equation % Survival=
(
x−n̂
p̂−n̂
)
×100. 
Where x equals the experimental value, p̂ equals the mean of 
the positive controls, and n̂ equals the mean of the negative 
controls.
2.3 | Whole cell rescue of MSM and SMM 
inhibition by amino acid supplementation
Wild‐type (WT) M bovis BCG was grown to mid‐log density 
(OD600nm 0.4‐0.8) and diluted into 2 × Middlebrook 7H9 to 
2 × 106 cells/mL. Mixtures of leucine, isoleucine and valine, 
and of all 20 amino acids, or 20 mixtures of 19 amino acids 
(each mixture lacking a different amino acid) were made at 
2× required concentration (stated where appropriate) and ad-
justed to pH 7.4. MSM and SMM were added into Greiner 
black flat‐bottomed 96‐well plates. Cells and amino acid 
mixtures were mixed in equal volumes to attain 1 x 7H9 con-
centration with 1 × 106 cells/mL. 7H9 with cells and amino 
acids were then added to each well up to 100 μL at a final 
concentration of up to 2% DMSO. The 96‐well plates were 
then incubated for 7 days at 37°C with 5% CO2. After incuba-
tion, cell survival was monitored using the resazurin assay as 
described.18
2.4 | Spontaneous resistant mutant 
generation and WGS
Mycobacterium bovis Bacillus Calmette‐Guérin (BCG) 
resistant mutants were generated by plating 1 × 108 mid‐
log cells on solid media (7H11 agar with 10% OADC and 
0.2% glycerol) containing 0, 10, 20, 30, 40, and 50 μmol/L 
of MSM or SMM. Plates were incubated at 37°C, 5% CO2, 
until the growth of colonies. Spontaneous resistant mu-
tants were confirmed by testing their Minimum Inhibitory 
Concentration (MIC) in liquid media as described above. The 
genomic DNA from validated mutants was extracted and sent 
to MicrobesNG for WGS.
2.5 | Generation of mycobacterial over‐
expression constructs
The mycobacterial over‐expression constructs pV-
V16k‐ilvB1‐ilvN, pVV16k‐ilvN and pMV261a‐ilvB1 were 
generated using standard cloning techniques. Briefly, 
the WT and mutant genes were amplified from WT and 
spontaneous‐resistant mutant genomic DNA by PCR (Q5 
High Fidelity DNA Polymerase, NEB) using primers de-
scribed in Table 1 (Eurofins Genomics). The PCR products 
were cloned into the appropriate vector by exploiting the 
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restriction sites introduced in the primer (as stated in Table 
1). All constructs were confirmed by sequencing (Source 
Biosciences).
3 |  RESULTS
3.1 | Development of high‐throughput 
screening assay to identify inhibitors of amino 
acid biosynthesis
In the TB drug discovery pipeline, identification of the in-
hibitor target is a fundamental step toward validating the drug 
potential of a particular compound or scaffold. Target identifi-
cation commonly involves the WGS of spontaneous‐resistant 
mutants against compounds that have shown anti‐tubercular 
activity from a whole throughput screening campaign. There 
are a number of reported successes when using this ap-
proach.3,19-21 However, to avoid the discovery and progres-
sion of compounds that inhibit inappropriate targets, we have 
developed a new strategy to identify inhibitors of a specific set 
of biochemical pathways: amino acid biosynthesis. We have 
designed a high‐throughput phenotypic screen, which can be 
used to find inhibitors of any amino acid biosynthetic pathway, 
or tailored to that of a defined amino acid. In this method, we 
supplemented the growth media with all amino acids, allow-
ing bacteria to survive in the presence of an amino acid bio-
synthetic inhibitor. To validate this screen, we used MSM and 
SMM, known inhibitors of branched‐chain amino acid syn-
thesis, which specifically target IlvB1.22 M bovis BCG was 
subjected to 5, 10, 20, and 30 μmol/L of MSM and SMM, and 
supplemented with increasing concentrations of all 20 amino 
acids up to 500 μmol/L (Figure 1). As the concentration of the 
amino acids increases, the level of bacterial survival increases 
indicating that M bovis BCG can be rescued from MSM and 
SMM inhibition with amino acid supplementation.
3.2 | Identification of the amino acid 
pathway targeted by an inhibitor
Following the identification of an inhibitor of amino acid bio-
synthesis, the specific targeted pathway can be elucidated. By 
supplementing the growth media with 1 mmol/L of 19 of the 
20 amino acids, cell survival can be monitored in the presence 
of the inhibitor. This was validated by assessing M bovis BCG 
survival using 50 μmol/L of MSM or SMM (Figure 2A, B). 
When the three branched‐chain amino acids valine, leucine, 
and isoleucine were individually excluded from the media, the 
mycobacteria were unable to survive in the presence of the in-
hibitor. In the individual absence of all other amino acids, the 
cells were able to survive. The exclusion of proline from the 
growth media is shown as a control example in Figure 2A, B. 
It is noteworthy that in this screen, when one branched‐chain TA
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F I G U R E  1  Amino acid supplementation 
rescues inhibition of Mycobacterium bovis 
BCG by metsulfuron‐methyl (MSM) and 
sulfometuron‐methyl (SMM). Dose response 
graph showing M bovis BCG rescue 
from increasing (A) MSM and (B) SMM 
concentrations with increasing concentrations 
of all 20 amino acids supplemented into the 
growth media. Data are displayed as the mean 
and SD of n = 3. Structures of MSM and 
SMM are also displayed. The data are colored 
according to the specified drug concentration
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F I G U R E  2  Confirmation of the 
amino acid biosynthetic pathway targeted 
by metsulfuron‐methyl (MSM) and 
sulfometuron‐methyl (SMM) inhibition. 
A, 50 μmol/L MSM and B, 50 μmol/L 
SMM inhibition of M bovis BCG when 
supplemented with media containing 
1 mmol/L of 19 amino acids. The omitted 
amino acid is displayed. Each spot is 
based on a single experiment. (C,D) Dose 
response graph showing M bovis BCG 
rescue from increasing (C) MSM and 
(D) SMM concentrations with increasing 
concentrations of valine, leucine, and 
isoleucine supplemented into the growth 
media. The data are colored according 
to the specified drug concentration. Data 
are displayed as the mean and standard 
deviation of n = 3
(A)
(B)
(C) (D)
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amino acid was absent from the media, survival was not pos-
sible, indicating that all three amino acids are required to 
rescue MSM and SMM inhibition. To confirm that only va-
line, leucine, and isoleucine were required for survival, in the 
presence of MSM or SMM, the amino acid supplementation 
was repeated with the three amino acids and full survival was 
achieved (Figure 2C,D). These results are consistent with the 
experiments performed by Awasthy and co‐workers.6
3.3 | MSM and SMM target identification
Subsequent to the discovery of an inhibitor of an amino acid 
biosynthetic pathway, the precise mode of action can then 
be determined. This can be achieved through a number of 
techniques, including WGS of resistant isolates, and over‐ex-
pression studies of the genes involved in the particular bio-
synthetic pathway.3,19-21 Although it is known that the control 
compounds MSM and SMM target the essential IlvB1 en-
zyme,22 WGS of resistant isolates was performed to identify 
resistance‐conferring mutations within the gene. This can 
provide valuable information regarding the inhibitor binding 
site and for compound optimization.
Initially, the MIC of MSM and SMM was established on 
solid media: 7.5 and 20 μmol/L, respectively. Spontaneous 
resistant isolates were raised at 50 μmol/L, and the resistance 
phenotype was confirmed by MIC determination in liquid 
media. The gDNA from three mutants per compound was an-
alyzed by WGS and the results are shown in Table 2. As ex-
pected, each mutant was found to contain a single‐nucleotide 
polymorphism (SNP) in ilvB1 of greater than 50% mutational 
frequency within the population. Interestingly, SNPs were 
also identified in ilvN, the regulator of IlvB1 activity. In the 
six mutant sequences, four different SNPs were identified in 
ilvB1, whereas the same SNP was present in ilvN.
To corroborate that the mutations in ilvB1 and ilvN were 
responsible for resistance to MSM and SMM, the impact of 
over‐expressing ilvB1 and ilvN on the MIC of the compounds 
was investigated and the results are shown in Figure 3. WT 
and mutant versions of ilvB1 and ilvN were cloned into the 
mycobacterial expression vectors pMV261a and pVV16k, 
respectively, and the constructs were electroporated into 
M smegmatis. Over‐expression of WT ilvB1 and ilvN indi-
vidually showed no improvement in survival when MSM 
and SMM were added to the medium. Over‐expression of 
both ilvB1 and ilvN together in pVV16k showed a marginal 
increase in resistance. However, over‐expression of mutant 
ilvB1 resulted in a significant increase in resistance, but over‐
expression of mutant ilvN alone showed no improvement in 
the ability to survive in the presence of the compounds. Over‐
expression of both mutant genes showed a similar increase in 
resistance compared to when over‐expressing mutant ilvB1 
alone. These results further show that IlvB1 is the target of 
MSM and SMM, and the mutations in ilvN, although are un-
able to confer resistance, are likely to be compensatory.
3.4 | Discovery of inhibitors against amino 
acid biosynthesis
In order to benefit from this novel method of identifying in-
hibitors of amino acid biosynthesis, a GlaxoSmithKline (GSK) 
compound library consisting of 227 non‐cytotoxic anti‐tubercu-
lar compounds (the ‘TB box set’) was screened.23,24 With a fixed 
T A B L E  2  Whole genome sequencing data for Mycobacterium bovis BCG spontaneous resistant mutants raised against MSM and SMM. The 
genomic location of the SNP and the respective gene in which it occurs is stated, along with the codon (the capital letter denotes the base change) 
and corresponding amino acid residue substitutions. The percentage frequency of the mutation within the gDNA sequenced is stated and 
corresponds to the frequency of the mutation in the cell population
Compound Mutant x MIC MSM x MIC SMM
Genome 
position of SNP Gene Base change
Amino acid 
substitution
Mutational 
frequency (%)
MSM 1 x6.6 x2.5 3361440 ilvB1 tGg/tTg Trp516Leu 100
3360982 ilvN aCc/aTc Thr50Ile 100
2 x6.6 x2.5 3362036 ilvB1 gaC/gaA Asp317Glu 100
3360982 ilvN aCc/aTc Thr50Ile 100
3 x6.6 x2.5 3362791 ilvB1 Ccg/Tcg Pro66Ser 100
3360982 ilvN aCc/aTc Thr50Ile 100
SMM 1 x6.6 x2.5 3361440 ilvB1 tGg/tTg Trp516Leu 100
3360982 ilvN aCc/aTc Thr50Ile 100
2 x6.6 x2.5 3362791 ilvB1 Ccg/Tcg Pro66Ser 100
3360982 ilvN aCc/aTc Thr50Ile 100
3 x6.6 x2.5 3362577 ilvB1 gTc/gCc Val137Ala 67.5
3360982 ilvN aCc/aTc Thr50Ile 100
MSM, metsulfuron‐methyl; SMM, sulfometuron‐methyl.
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compound concentration of 20 μmol/L, survival of M bovis 
BCG was established in the presence and absence of 1 mmol/L 
amino acid supplementation. The amino acid supplementation 
was shown to rescue cell viability against a single compound, 
compound 1 (Figure 4). The amino acid pathway targeted by 
compound 1 was then elucidated using the method of individual 
amino acid exclusion from the media. It was discovered that 
when tryptophan was omitted from the media, M bovis BCG 
was unable to survive in the presence of compound 1, giving 
a strong indication that the compound targeted tryptophan bio-
synthesis (Figure 4). Unexpectedly, the precise mode of action 
of this compound has previously been elucidated3, but the ra-
tional and validity of this approach remain evident.
4 |  DISCUSSION
In TB drug discovery, whole‐cell phenotypic high‐through-
put screening campaigns of extensive compound libraries 
have dominated the discovery of anti‐tubercular compounds, 
which have the potential for progression into drug candi-
dates.23-25 This current change in strategy from the traditional 
in vitro enzyme‐specific screens has yielded new inhibitors 
with unprecedented successes, but not without limitations. 
With unknown targets, significant amounts of money can be 
spent pursuing potent inhibitors of unsuitable targets that is, 
with homologous counterparts in humans. Therefore, under-
standing the mode of action of an inhibitor is crucial in the 
early stages of drug discovery, facilitating the progression of 
medicinal chemistry efforts that turn hits into leads and new 
drug candidates.
Until recently, target assignment of anti‐tubercular drugs 
from screening campaigns has typically relied upon the gener-
ation and genome sequencing of resistant mutants. Although 
this remains a validated approach, discovery of new potential 
inhibitory compound scaffolds has taken a different direction 
toward phenotypic target‐based high‐throughput screening 
methods. In this work, we have developed a high‐throughput 
F I G U R E  3  Impact on the MIC of metsulfuron‐methyl (MSM) and sulfometuron‐methyl (SMM) with the over‐expression of IlvB1 and IlvN. 
The pMV261a and pVV16k constructs containing WT ilvB1, ilvB1‐D317E, ilvB1‐P66S, WT ilvN, ilvN‐T50I, and combinations of both WT and 
mutant ilvB1 with ilvN were over‐expressed in M smegmatis and the MIC of (A) MSM and (B) SMM was analyzed. Data are displayed as the mean 
and standard deviation of n = 3
(A) (B)
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phenotypic screen to identify inhibitors of amino acid bio-
synthesis. Amino acid biosynthesis is an example of a prom-
ising pathway to target with anti‐tubercular agents, which has 
currently been underexploited. Amino acids are fundamen-
tal to all forms of life. Mycobacteria have the machinery to 
synthesize all amino acids de novo. The enzymes involved 
are essential, enabling the cells to survive in the absence of 
an external source. While mycobacteria can scavenge amino 
acids from their surroundings in vitro, evidence from aux-
otroph and transporter studies suggests that at least seven 
amino acids cannot be scavenged enough in mice or mac-
rophages to compensate auxotrophy.9-12,14,16 In humans, nine 
amino acids are classified as essential and must be acquired 
through diet: histidine, isoleucine, leucine, methionine, phe-
nylalanine, threonine, tryptophan, and valine. Targeting the 
discovery of drugs against these specific biosynthetic path-
ways would alleviate the concern of a common target in hu-
mans, reducing the potential toxicity. Additionally, long‐term 
oral treatment with inhibitors against amino acid biosynthetic 
pathways would unlikely effects the gastrointestinal flora, 
which is rich in amino acids, further protecting against com-
pound toxicity.7 These features make amino acid biosynthesis 
in Mtb a plausible route to target in drug discovery, and the 
essential nature of these processes infers that they also have 
the potential of broad‐spectrum activities.
To discover inhibitors specifically against amino acid 
biosynthesis, we have optimized a phenotypic screen using 
known inhibitors of branched‐chain amino acid biosynthesis. 
Media supplemented with all amino acids have advantages 
over single amino acid supplementation; for some amino 
acids, there are multiple routes to their synthesis, and some 
pathways, such as branched‐chain amino acid biosynthesis, 
are linked. Therefore, single amino acid supplementation into 
the media may not provide resistance. For example, as Figure 
2A and B show, even with two branched‐chain amino acids 
in the media, this is not sufficient to rescue survival in the 
presence of MSM or SMM. Previous studies have confirmed 
that these inhibitors target the heterotetramer acetohydroxy-
acid synthase, formed of the catalytic subunit, IlvB1, and the 
regulatory subunit, IlvN. IlvB1 functions to generate aceto-
lactate from two molecules of pyruvate, precursor to valine 
and leucine, and also is involved in a separate pathway to gen-
erate acetohydroxybutanoate from combining pyruvate and 
oxobutanoate, leading to the synthesis of isoleucine shown in 
Figure 5. This is described fully in an excellent review of bac-
terial branched‐chain amino acid synthesis.26 Interestingly, 
bioinformatic analysis of the Mtb genome has revealed that 
other catalytic subunits exist: ilvB2, ilvG and ilvX; ilvB2 has 
low sequence homology with the other three genes. Although 
it not known whether IlvB2, IlvG, or IlvX are also inhibited 
by MSM and SMM, WGS analysis only revealed mutations 
in IlvB1 and IlvN, suggesting that IlvB1 plays the major cat-
alytic role of the acetohydroxyacid synthase activity. Studies 
investigating the roles of the different catalytic subunits have 
shown that they are differentially expressed under differ-
ent physiological conditions, including in stationary phase, 
hypoxia, and stress conditions.27 The survival studies per-
formed in this work were conducted when the cells were in 
exponential growth phase, where it has been shown that ilvB1 
transcription is elevated compared to in stationary phase.27 It 
is therefore plausible that the other catalytic subunits cannot 
compensate for IlvB1 inhibition by MSM and SMM due to 
their differential expression levels during mid‐exponential 
growth.
It has previously been established that in vitro IlvB1 is 
the target of MSM and SMM, and that the acetohydroxy-
acid synthase activity and inhibition is not reliant on the 
presence of the regulatory subunit, IlvN.22 However, the 
over‐expression studies in this work have demonstrated that 
increasing the cellular levels of IlvB1 alone is not sufficient 
to increase the resistance against SMM and MSM, whereas 
F I G U R E  4  Identification of the amino acid biosynthetic pathway targeted by compound 1. Mycobacterium bovis BCG was challenged with 
5 μmol/L compound 1 in media supplemented with 19 amino acids. The mycobacteria were not viable in the absence of tryptophan, indicating the 
target pathway. The omittance of tryptophan and other amino acids from the supplemented media is shown, where each spot represents a single 
experiment. The structure of compound 1 is also displayed
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over‐expression of both subunits concomitantly does en-
able cell survival in the presence of high concentrations 
of inhibitor. In vivo, acetohydroxyacid synthase exists as a 
heterotetramer, and it is likely that IlvN controls the confor-
mation of IlvB1, regulating its activity. Choi and co‐work-
ers have demonstrated that IlvN does enhance the activity 
of IlvB1 in vitro. Therefore, over‐expression of IlvB1 alone, 
although increasing the copy number of the target within 
the cell, with only native expression levels of IlvN, the 
conformation may not be suitable to compensate for those 
complexes inhibited by SMM or MSM, or be in a suitable 
conformation for inhibition. The activity of the IlvB1 in 
vitro indicates that the enzyme is in a suitable conformation 
for activity in the absence of IlvN, which may be a result of 
the expression of the recombinant protein. Over‐expression 
of mutant IlvB1 alone did increase the MIC of SMM and 
MSM. It is likely that the mutated catalytic subunit replaces 
the WT copies in the heterotetramer, enabling the enzyme 
to function in the presence of the inhibitors. WT or mu-
tant IlvN over‐expression did not increase the MIC of the 
inhibitors, suggesting that the inhibitors do not target the 
regulation of IlvB1 activity and that the mutation in IlvN 
revealed by WGS is likely to compensate for any conforma-
tional changes imparted by the mutations in IlvB1.
Amino acid biosynthesis, although previously sug-
gested as a suitable target for the discovery of anti‐tubercu-
lar drugs,3,7,17,28 has been largely unexplored. Target‐based 
screens, be it in vitro kinetic assays or whole cell assays, have 
been historically exploited to successfully identify inhibitors 
of a specific enzyme. This method is not without limitations; 
screening for inhibitors of a particular enzyme eliminates the 
possibility of discovering inhibitors against other enzymes 
within the same biochemical pathway. In this work, we have 
developed a whole‐cell high‐throughput phenotypic screen to 
discover inhibitors of amino acid biosynthesis. This screen 
not only ensures compound entry into the cell, but also en-
ables the broad range discovery of inhibitors that can target 
any point in amino acid biosynthesis and not directed toward 
a single enzyme. Using the GSK “TB box” set of anti‐tu-
bercular compounds, we identified an inhibitor of tryptophan 
biosynthesis, which has previous confirmed activity against 
tryptophan synthase.3 This validates the undeniable potential 
of the screen in the future discovery of inhibitors of amino 
acid biosynthesis.
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